Asylum, Covalent partner for industrial atomic force microscopy
Oxford Instruments Asylum Research and Covalent Metrology Services have partnered to develop and promote commercial applications for atomic force microscopy. Read More
Codiak presents preclinical results for modular vaccine platform
Codiak BioSciences released new preclinical data on its engEx platform at the American Society of Gene and Cell Therapy annual meeting. Read More
Roche becomes founding partner of biotech accelerator
Roche has become a founding partner in the second phase of development of BaseLaunch, a Basel, Switzerland-based incubator and accelerator that helps scientists and entrepreneurs launch biotech companies. Read More
Nasal, oral antiseptics show antiviral activity against SARS-CoV-2
Veloce BioPharma has reported that its nasal and oral antiseptics are effective against SARS-CoV-2, the virus responsible for COVID-19. Read More
Exyte, Univercells fast track construction for COVID-19 vaccines
High-tech construction firm Exyte and biomanufacturing company Univercells Technologies are partnering for construction of modular standardized and flexible manufacturing facilities for vaccines. Read More
Boehringer Ingelheim acquires Northern Biologics
Boehringer Ingelheim on May 14 announced the acquisition of Northern Biologics, including its preclinical cancer antibody pipeline. Read More
Avrobio moves forward with gene therapy candidate
Avrobio released preclinical data for AVR-RD-03, lentiviral gene therapy for Pompe disease, at the American Society of Gene and Cell Therapy annual meeting on May 14. Read More
Glenmark begins phase III trials for favipiravir
Glenmark has launched phase III clinical trials in India to assess the use of its favipiravir antiviral tablets on COVID-19 patients. The drug is a generic version of Fujifilm Toyama Chemical's Avigan. Read More
Yumab identifies COVID-19 antibody therapy
German biotechnology company Yumab said it has identified a promising candidate for COVID-19 antibody therapy. Read More
BARDA gives $20M to Sabin Vaccine Institute for vaccines
The U.S. Biomedical Advanced Research and Development Authority (BARDA) awarded the Sabin Vaccine Institute $20 million to manufacture and release clinical Ebola and Marburg vaccine materials developed by its partner, ReiThera. The funding will also support nonclinical studies to evaluate their efficacy and immune response. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter